Imipramine in Absence & Myoclonic-astatic Seizures
Neurol 28:953-957, Fromm,G.H.,et al, 1978
Fomepizole for Ethylene Glycol and Methanol Poisoning
NEJM 360:2216-2223, Brent,J., 2009
Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease
Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008
Fomepizole for the Treatment of Methanol Poinsoning
NEJM 344:424-429, Brent,J.,et al, 2001
Comtan (Entacapone) The Treatment of Parkinson's Disease, Questions & Answers
APDA Ed Suppl #15, Watts,R.L., 2001
Extrapyramidal Side Effects with Low-Dose Risperidone
Can J Psychiatry 42:325-325, Brown, E.S., 1997
Drug Treatment of Alzheimer's Disease, Raise Clinical and Ethical Problems
BMJ 314:693-694, Kelley,C.A.,et al, 1997
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter 39:53-54, , 1997
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
NEJM 336:1216-1222, 12451997., Sano,M.,et al, 1997
Tolcapone in Stable Parkinson's Disease:Efficacy and Safety of Long-Term Treatment
Neurol 49:665-671, Waters,C.H.,et al, 1997
Vascular Effects of Statins in Stroke
Stroke 28:2315-2320, Delanty,N.&Vaughan,C.J., 1997
COMT Inhibition with Tolcapone Reduces the"Wearing Off"Phenomenon & Levodopa Requirements in Fluctuating Parkinsonisn Pts
JNNP 63:421-428, Baas,H.,et al, 1997
Tolcapone Improves Motor Function in Parkinsonian Pts with the"Wearing Off"Phenomenon
Neurol 49:1066-1071, Rajput,A.H.,et al, 1997
Entacapone Improves Motor Fluctuations in Levodopa-Treated Parkinson's Dis Pts
Parkinson Study Group, Ann Neurol 42:747-7551997., , 1997
The Use of Sumatriptan in Patients with Monoamine Oxidase Inhibitors
Neurol 45:1039-1040, Diamond,S., 1995
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents
J Clin Psychiatry 55:38-45, DeVane,C.L., 1994
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
Deprenyl Effects of Levodopa Pharmacodynamics, Mood, and Free Radical Scavenging
Neurol 42:541-544, Baronti,F.,et al, 1992
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
Selegiline Use to Prevent Progression of Parkinson's Disease
Arch Neurol 46:1275-1279, Elizan,T.S.,et al, 1989
MPTP:A Neurotoxin Relevant to the Pathophysiology of Parkinson's Disease, The 1985 George Cotzias Lecture
Neurol 36:250-258, Snyder,S.H.&D'Amato,R.J., 1986
Pyridoxine Deficiency & Peripheral Neuropathy Associated with Long-Term Phenelzine Therapy
Am J Med 75:887-888, Heller,C.A.,et al, 1983
Deprenyl In Parkinson's Disease
Lancet 2:695-696, , 1982
Deprenyl in Parkinson Disease
Neurol 31:19-23, Eisler,T.,et al, 1981
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976
Monoamine Oxidase Inhibitor & L-Dopa
BMJ 3:388, Hunter,H.R.,et al, 1970